Actemra (tocilizumab)
Rheumatoid Arthritis
ApprovedCommercial
Key Facts
About Chugai Pharmaceutical
Chugai Pharmaceutical Co., Ltd. is Japan's premier biotechnology company and a subsidiary of Roche, focusing on precision medicine and innovative drug development. Founded in 1925, the company has built a strong portfolio in oncology, autoimmune diseases, and rare conditions through both in-house R&D and strategic partnerships with Roche. Chugai operates as Roche's key development and commercialization hub in Japan while maintaining its independent research capabilities and Tokyo Stock Exchange listing.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| CORTONE (cortisone) | Merck | Commercial |
| Kevzara (sarilumab) | Regeneron Pharmaceuticals | Approved |
| Tocilizumab | Biocon | Filed |
| Humira | Abbott India | Approved |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 2 |
| Tibulizumab (ZB-106) | Zura Bio | Phase 1b |
| Zunsemetinib (ATI-450) | Aclaris Therapeutics | Phase 2b |
| Natrunix Program | XBiotech | Not Specified |
| LEAPS Technology | CEL-SCI | Pre-clinical |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase 3 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |